Vitro Biopharma, Inc. financial data

Symbol
VTRO on NYSE
Industry
Biological Products, (No Diagnostic Substances)
Location
3200 Cherry Creek Drive South, Suite 410, Denver, Colorado
State of incorporation
Nevada
Fiscal year end
October 31
Former names
VITRO DIAGNOSTICS INC (to 10/20/2021)
Latest financial report
Q1 2024 - May 31, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 39.9 %
Quick Ratio 2.57 %
Debt-to-equity -344 %
Return On Assets -131 %
Operating Margin -412 % +5.69%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.46M shares -96.1%
Common Stock, Shares, Outstanding 4.46M shares -96.1%
Entity Public Float 0 USD
Common Stock, Value, Issued 4.46K USD -96.1%
Weighted Average Number of Shares Outstanding, Basic 4.46M shares +0.68%
Weighted Average Number of Shares Outstanding, Diluted 4.46M shares +0.68%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 573K USD +86.1%
Revenue from Contract with Customer, Excluding Assessed Tax 2.11M USD +21.4%
Research and Development Expense 429K USD +167%
Operating Income (Loss) -8.69M USD -14.5%
Net Income (Loss) Attributable to Parent -10.5M USD -35%
Earnings Per Share, Basic -2.35 USD/shares +3.69%
Earnings Per Share, Diluted -2.35 USD/shares -119%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 181K USD -92.8%
Accounts Receivable, after Allowance for Credit Loss, Current 157K USD +230%
Inventory, Net 182K USD -19.1%
Assets, Current 2.12M USD -19.7%
Property, Plant and Equipment, Net 229K USD -20.7%
Operating Lease, Right-of-Use Asset 410K USD +62.9%
Intangible Assets, Net (Excluding Goodwill) 634K USD -51.7%
Goodwill 3.61M USD 0%
Other Assets, Noncurrent 8.44K USD -39.1%
Assets 7.09M USD -13%
Accounts Payable, Current 2.18M USD +138%
Accrued Liabilities, Current 1.55M USD +61.8%
Liabilities, Current 10.4M USD +265%
Operating Lease, Liability, Noncurrent 285K USD +39.6%
Liabilities 14.7M USD +102%
Retained Earnings (Accumulated Deficit) -35.8M USD -41.2%
Stockholders' Equity Attributable to Parent -7.56M USD -954%
Liabilities and Equity 7.09M USD -13%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.2M USD -26.4%
Net Cash Provided by (Used in) Financing Activities 2.98M USD +666%
Net Cash Provided by (Used in) Investing Activities -486 USD
Common Stock, Shares Authorized 19.2M shares -96.2%
Common Stock, Shares, Issued 4.46M shares -96.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.66M USD +561%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.89K USD -15.6%
Deferred Tax Assets, Valuation Allowance 5.05M USD +36.2%
Deferred Tax Assets, Gross 5.05M USD +36.2%
Operating Lease, Liability 410K USD +62.9%
Depreciation 167K USD +0.2%
Payments to Acquire Property, Plant, and Equipment 121K USD -60.8%
Lessee, Operating Lease, Liability, to be Paid 677K USD +39.4%
Property, Plant and Equipment, Gross 1.06M USD +11.3%
Operating Lease, Liability, Current 125K USD +163%
Lessee, Operating Lease, Liability, to be Paid, Year Two 167K USD +146%
Lessee, Operating Lease, Liability, to be Paid, Year One 164K USD +384%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 267K USD +14.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 84.6K USD +24.9%
Deferred Tax Assets, Operating Loss Carryforwards 3.07M USD +42.1%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 67.7K USD 0%
Operating Lease, Payments 56.9K USD +11.1%
Additional Paid in Capital 28.3M USD +8.06%
Amortization of Intangible Assets 99.8K USD -44.1%
Interest Expense 2.51M USD +1345%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%